Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Lambda-carrageenan to preparation of immunologic adjuvant and antigen-adjuvant compound

A technology of immune adjuvant and carrageenan, which is applied in the field of biomedicine, can solve the problems of preparing vaccines, and achieve the effect of high clinical safety, simple method and strong immune activity

Inactive Publication Date: 2015-08-19
SICHUAN UNIV
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no report on the preparation of vaccines with carrageenan as an immune adjuvant

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Lambda-carrageenan to preparation of immunologic adjuvant and antigen-adjuvant compound
  • Application of Lambda-carrageenan to preparation of immunologic adjuvant and antigen-adjuvant compound
  • Application of Lambda-carrageenan to preparation of immunologic adjuvant and antigen-adjuvant compound

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] Example 1 OVA vaccine prepared using λ-carrageenan as an adjuvant and its immunotherapy experiment

[0041] Experimental materials and reagents: λ-carrageenan (CAT.22049) and OVA (CAT.A5503) were purchased from Sigma Company in the United States; C57BL / 6 mice were purchased from Beijing Weitong Lihua Company; mouse lymphoma cells EG .7-OVA was purchased from ATCC in the United States; ELISA self-coated plates were purchased from NUNC.

[0042] (1) Preparation of OVA vaccine

[0043] Preparation of OVA solution: Weigh 10 mg of OVA and dissolve it in 10 mL of normal saline to make a solution with a concentration of 1 mg / mL; then dilute 10 times with normal saline to obtain a stock solution of 0.1 mg / mL.

[0044] Preparation of λ-carrageenan solution: 10 mg λ-carrageenan was weighed and dissolved in 5 mL of normal saline to prepare a stock solution with a concentration of 2 mg / mL.

[0045] Take 50 μl of the prepared OVA and λ-carrageenan solutions and mix them in equal v...

Embodiment 2

[0053] Example 2 Discussion on the Immunological Activation of λ-Carrageenan

[0054] Experimental materials and reagents: λ-carrageenan was purchased from Sigma Company (CAT.22049) in the United States; C57BL / 6 mice were purchased from Beijing Weitong Lihua Company; mouse melanoma B16-F10 was purchased from ATCC in the United States; Antibodies for flow cytometry were purchased from BD-Pharmingen, USA.

[0055] (1) Effects of λ-carrageenan treatment on immune function in mice

[0056] B16-F10 tumors were placed subcutaneously on the right side of the mouse, 10 6 / mouse, when the tumor was palpable (about 3mm, 3-5 days after inoculation), the mice were randomly divided into two groups, and the mice began to be injected with normal saline NS and λ-carrageenan intratumorally, 50mg / kg body weight, once a day.

[0057] At the later stage of λ-carrageenan treatment, 3 mice in each group were sacrificed, the tumor tissue was cut into pieces and digested with collagenase to obtai...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of biological medicine, and relates to application of algal polysaccharides to a vaccine adjuvant. The invention aims at solving the technical problem that the ideal adjuvant for vaccine preparation, particularly for tumor vaccine preparation is difficult to obtain. In order to solve the technical scheme, the invention provides a new purpose of Lambda-carrageenans to preparation of an immunologic adjuvant. The Lambda-carrageenans are disaccharide units formed by connecting 2-sulfated galactose and 2, 6-sulfated galactose through beta-1, 4 keys, and each disaccharide unit is provided with polysaccharides of three sulfating sites. The tumor vaccine prepared by using the Lambda-carrageenans as the adjuvant can obviously enhance the serum antibody titers of the antigen, and can reduce the tumor formation rate of mice, the obvious anti-tumor effect is achieved, and the new selection is provided for the development and the application of the vaccine.

Description

technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to the application of λ-carrageenan as a vaccine adjuvant, and an antigen-adjuvant complex using λ-carrageenan as an adjuvant. Background technique [0002] For vaccines, the addition of adjuvants is crucial. Adjuvant is a non-specific immune enhancer, which has been used for decades to improve the body's immune response to vaccine antigens. Injecting the antigen into the body together with the adjuvant can reduce the amount of antigen required for effective immunization and the frequency of immunization, improve the success rate of early immune response and immune insufficiency, and so on. [0003] Carrageenan is a polysaccharide extracted from the cell wall of marine red algae, which is composed of 2-sulfated galactose and 2,6-sulfated galactose linked by β-1,4 bonds. According to the number and position of sulfated sites, carrageenan can be divided into three types: κ-, ι...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/39A61K39/00A61K39/29A61P35/00A61P1/16A61P31/20A61P31/14
Inventor 罗敏魏霞蔚魏于全
Owner SICHUAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com